Is Vertex Pharmaceuticals Stock a Millionaire Maker?
Vertex Pharmaceuticals (NASDAQ: VRTX) is a growing pharmaceutical company with a robust cystic fibrosis (CF) business that generated nearly $10 billion in revenue last year. While there is still more room for the business to get bigger, Vertex is already at a sizable market cap of $100 billion. Does this stock have enough runway to generate significant returns and help you become a millionaire in the long run?
Vertex is more than just a CF company, and that's why many growth investors remain bullish on its prospects -- they know there are more growth catalysts out there. Vertex's growth opportunities take the company down multiple avenues, including a non-opioid pain medication that has shown promise in clinical trials.
VX-548 is a non-opioid treatment for pain which could be a game changer for the healthcare industry, giving patients a way to address pain with much less fear of getting addicted to opioids. The company plans to apply for regulatory approval this year. At its peak, VX-548 may generate $5 billion in annual revenue for Vertex.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
With 40 Buy predictions and 2 Sell predictions Vertex Pharmaceuticals Inc. is one of the favorites of our community.
As a result the target price of 382 € shows a slightly positive potential of 2.23% compared to the current price of 373.65 € for Vertex Pharmaceuticals Inc..
